Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 12 (4), 396-401

Acute Toxicity Associated With Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists With Analytical Confirmation

Affiliations
Case Reports

Acute Toxicity Associated With Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists With Analytical Confirmation

Rachelle Abouchedid et al. J Med Toxicol.

Abstract

Introduction: Synthetic Cannabinoid Receptor Agonists (SCRAs) are the largest group of new psychoactive substances reported to the European Warning System and the United Nations Office on Drugs and Crime to date. The heterogeneous nature and speed of diversification of these compounds make it challenging to accurately characterise and predict harms of these compounds in pre-clinical studies, ahead of their appearance.

Case report: We report the case of a 19-year-old female who purchased three products from a headshop: two new psychoactive substances (sachets of "cannabis tea" and "mushroom tea") as well as two LSD blotters. After the "cannabis tea" was smoked and the two LSD blotters and "mushroom tea" were ingested, the patient became tachycardic (HR 128), developed seizures, agitation, visual hallucinations as well as suspected serotonergic toxicity (sustained ankle clonus 20-30 beats) 1-2 hours after use. She was treated with 1 mg of intravenous midazolam. Symptoms/signs resolved within 13 hours. No further supportive care was required. Plasma, blood, and urine samples confirmed the presence of two SCRAs: 5FAKB-48 and 5F-PB-22. The patient also reported therapeutic use of both fluoxetine and citalopram for depression.

Discussion: To the best of our knowledge, this is the first case report of non-fatal intoxication with 5F-AKB-48 with analytical confirmation and exposure times. It also highlights the difficulties in understanding the pattern of toxicity of certain SCRAs in the context of psychotropic medications/co-morbid mental illness.

Keywords: 5F-AKB-48; 5F-PB-22; Novel psychoactive substances; Recreational drug toxicity; Synthetic cannabinoid receptor agonist.

Conflict of interest statement

Authors Rachelle Abouchedid, James H. Ho, Simon Hudson, Alison Dines, John RH. Archer, David M. Wood and Paul I. Dargan declare that they have no conflict of interest. Professor Dargan reports that he is a member of the UK Advisory Council on the Misuse of Drugs and the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction. Sources of Funding None Informed Consent Consent for publication of this case was obtained and provided to the journal in accordance with JMT policy.

Figures

Fig. 1
Fig. 1
AKB-48 and 5F-AKB-48
Fig. 2
Fig. 2
PB-22 and 5F- PB-22

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

Publication types

MeSH terms

LinkOut - more resources

Feedback